COVID 19: RECENT VACCINE AND VACCINE UNDER TRAIL
AMISHA PATEL *
GCP,SBP, Odisha, India.
B. RAY
CPS, Puri(Under BPUT) Odisha, India.
ASHMAUL HUSSAIN
GCP,SBP, Odisha, India
P. K. BEHERA
School of Chemistry, SambalpurUniversity, Odisha, India.
*Author to whom correspondence should be addressed.
Abstract
Since 2002, there has been a record ofCoronavirus disease outbreak caused by SARS-CoV,MERS-CoV, as well as the novel SARS-CoV-2, the causalagent of the Coronavirus Disease 2019 that broke outin Wuhan, China in December the same year and hassince become widespread across several countries andcontinents leading to thousands of deaths More than 180 vaccine candidates, based on several different platforms(Fig. vaccine platform used for SARS-CoV-2 vaccine developement), are currently in development against SARS-CoV-2(57) (Fig. overview of the SARS-CoV-2 vaccine development landscape). TheWorld Health Organization (WHO) maintains a working document(57)that includes most of the vaccines in development and is available at https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Clinical trials are evaluating COVID-19 vaccines in tens of thousands of study participants to Generate the scientific data and other information needed to determine safety and effectiveness These clinical trials are being conducted by manufacturers according to rigorous standards.
Keywords: MERS-CoV, SARS-CoV-2, human par influenza, influenza virus